Skip to main content

Waters Acquires Blue Reference for $14M, Pays $3M to Settle IP Dispute

NEW YORK (GenomeWeb News) – Waters said in its Form 10-Q for the second quarter that it has acquired software firm Blue Reference for $14 million in cash.

In its document filed Friday with the US Securities and Exchange Commission, the company also disclosed a $3 million payment to settle litigation alleging patent infringement by Waters.

The Milford, Mass.-based company said that in July it acquired all the outstanding capital stock of Blue Reference, a developer and distributor of software products for the real-time mining and analysis of multiple application scientific databases and will integrate the Bend, Oregon-based firm's technology into Waters' software product platforms "to further differentiate and increase software offering revenues by providing customers with a more efficient scientific information assessment process."

Blue Reference's flagship product is its Paradigm Platform, an integrated collection of software services for constructing search-based applications "involving science objects," the company said on its website. "Our software applications give users a single access point to disparate and heterogeneous data sources in an easy-to-use and real-time manner," it said.

Waters also disclosed a $3 million payment in June to settle an IP lawsuit filed against it. It did not disclose the name of the plaintiff in the case, but as GenomeWeb Daily News' sister publication ProteoMonitor reported, on June 21 PerkinElmer filed a Notice of Voluntary Dismissal in its lawsuit against Waters. That lawsuit was filed at the end of February and accused Waters of infringing two patents covering mass spectrometry technology, US Patent Nos. 5,652,427 and 5,962,851.

A Waters spokesman declined to comment on the $3 million payment, citing the terms of the settlement agreement.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.